3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Colorectal Neoplasms
2
Uterine Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Interventions
Cyclophosphamide
39
fludarabine phosphate
37
Azacitidine
33
fludarabine
25
Whole-Body Irradiation
22
Busulfan
22
Tacrolimus
21
Antilymphocyte Serum
21
Mycophenolic Acid
19
Filgrastim
18
Methotrexate
16
Melphalan
15
venetoclax
13
Peripheral Blood Stem Cell Transplantation
13
Granulocyte Colony-Stimulating Factor
13
Cytarabine
13
thymoglobulin
12
Cyclosporine
12
Thiotepa
9
Cord Blood Stem Cell Transplantation
9
Alemtuzumab
8
Rituximab
7
Radiotherapy
7
Methylprednisolone
7
Decitabine
7
Clofarabine
7
Lenalidomide
6
Stem Cell Transplantation
5
Sirolimus
5
Nivolumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Myelodysplastic Syndromes
×
gedatolisib
×
Clear all
NCT02438761
2025-09-08
5
Institut Curie
Phase 2
Terminated
10 enrolled